Additionally, we studied the impact ofMYCNon the expression of VEGFs in primary NB and in NB cell lines

Additionally, we studied the impact ofMYCNon the expression of VEGFs in primary NB and in NB cell lines. were tendencies for the up-regulation of VEGF-A and D and the down-regulation of the hem/lymphangiogenesis inhibitors VEGFR-1 and sVEGFR-2 inMYCN-amplified tumors. Similarly,MYCN-transfection of the NB cell-line SH-EP induced up-regulation of VEGF-A and D and the switching-off of sVEGFR-2. == Conclusion == We provide evidence for the down-regulation of the lymphangiogenesis inhibitor sVEGFR-2 in metastatic NB stages, which may promote lymphogenic metastases. Down-regulation UK-383367 of hem- and lymphangiogenesis inhibitors VEGFR-1 and sVEGFR-2, and up-regulation of angiogenic activators VEGF-A and VEGF-D inMYCN-amplified stage 4 NB supports the high impact of this oncogene on NB progression. Keywords:Neuroblastoma, metastasis, vascularization, VEGFR-1, sVEGFR-2, VEGF-D, MYCN == Introduction == A key step in the malignant progression of tumors in adults is the angiogenic switch, the induction of blood vessels by hypoxic tumors (1,2). Additionally, tumor-induced lymphangiogenesis correlates frequently with the dissemination of tumor cells via lymphatic vessels. Hem- and lymphangiogenesis are robustly regulated by members of the Vascular Endothelial Growth Factor (VEGF) family: VEGF-A being (predominantly) hemangiogenic, and VEGF-C and D lymphangiogenic (35). In adults, hem- and lymphangiogenesis are associated with progressed tumor stages. Tumors of Rabbit polyclonal to baxprotein infants present a much broader spectrum of heterogeneity than those of adults, especially exemplified by the biology of neuroblastoma. Neuroblastoma (NB) is derived from sympatho-adrenal progenitor cells that migrate from the neural crest into target regions of the embryo. NB is mostly located along the sympathetic trunk ganglia and in the adrenal medulla. The spectrum of the disease ranges from complete spontaneous regression, which can be immediately observed in the special NB stage 4s – but may as well occur in early stages – to malignant progression into stage 4, with 5-year survival rates of less than 30%. Partial differentiation into ganglioneuroblastma is another developmental pathway (6). The most critical molecular predictor for the behavior and treatment of NB is theMYCNprotooncogene. Amplification (up to 150x) ofMYCNcharacterizes highly aggressive tumors and poor outcome despite intensive treatment (7). Staging of NB is performed according to the International Neuroblastoma Staging System (INSS). Stage 1 and 2 NBs are localized tumors, which have grown across the midline in stage 2. Metastasis to regional and systemic lymph nodes characterizes stages 3 and 4, respectively (8), indicating active interactions with the lymphovascular system. Additionally, high vascularity is characteristic for the progressed tumor stages (9,10), indicating an influence of blood capillaries on NB cell behavior and their typical dissemination into bone marrow. The impact of VEGFs on tumor hemangiogenesis and lymphangiogenesis has been shown in numerous studies of adult tumors, and several investigations in recent years have postulated a similar function for VEGFs in NB. Blood vessels and lymphatics are present in NB, and expression of the ligands VEGF-A, C and D as well as their receptors has been found (1113). Increased expression of VEGF-A has been described in NB stages 3 and 4 (14), while VEGF-C has been identified UK-383367 as a risk factor in stage 4 NB (15). High levels of VEGF-A have been found in stage 4 NB, but neither VEGF-A nor VEGF-C correlated with UK-383367 age,MYCNcopy number UK-383367 or lymph node metastasis (16). Moreover, it has been observed thatMYCNamplification correlates strongly with dense vascular supply, tumor dissemination and poor survival (9). According to Kang et al. (17),MYCNup-regulates VEGF-A, andMYCNamplified NBs exert.